Kim Won, Kim Dong Joon
Won Kim, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 156-707, South Korea.
World J Hepatol. 2014 Oct 27;6(10):688-95. doi: 10.4254/wjh.v6.i10.688.
Alcoholic hepatitis (AH) is an acute hepatic manifestation occurring from heavy alcohol ingestion. Alcoholic steatohepatitis (ASH) is histologically characterized by steatosis, inflammation, and fibrosis in the liver. Despite the wide range of severity at presentation, those with severe ASH (Maddrey's discriminant function ≥ 32) typically present with fever, jaundice, and abdominal tenderness. Alcohol abstinence is the cornerstone of therapy for AH and, in the milder forms, is sufficient for clinical recovery. Severe ASH may progress to multi-organ failure including acute kidney injury and infection. Thus, infection and renal failure have a major impact on survival and should be closely monitored in patients with severe ASH. Patients with severe ASH have a reported short-term mortality of up to 40%-50%. Severe ASH at risk of early death should be identified by one of the available prognostic scoring systems before considering specific therapies. Corticosteroids are the mainstay of treatment for severe ASH. When corticosteroids are contraindicated, pentoxifylline may be alternatively used. Responsiveness to steroids should be assessed at day 7 and stopping rules based on Lille score should come into action. Strategically, future studies for patients with severe ASH should focus on suppressing inflammation based on cytokine profiles, balancing hepatocellular death and regeneration, limiting activation of the innate immune response, and maintaining gut mucosal integrity.
酒精性肝炎(AH)是大量饮酒引起的一种急性肝脏表现。酒精性脂肪性肝炎(ASH)在组织学上的特征是肝脏出现脂肪变性、炎症和纤维化。尽管发病时严重程度范围广泛,但重度ASH患者(Maddrey判别函数≥32)通常表现为发热、黄疸和腹部压痛。戒酒是AH治疗的基石,对于较轻形式的AH,戒酒足以实现临床康复。重度ASH可能进展为多器官功能衰竭,包括急性肾损伤和感染。因此,感染和肾衰竭对生存率有重大影响,应对重度ASH患者进行密切监测。据报道,重度ASH患者的短期死亡率高达40%-50%。在考虑特定治疗之前,应通过现有的预后评分系统之一识别有早期死亡风险的重度ASH患者。皮质类固醇是重度ASH治疗的主要药物。当皮质类固醇禁忌时,可改用己酮可可碱。应在第7天评估对类固醇的反应性,并应根据里尔评分启动停药规则。从战略上讲,未来针对重度ASH患者的研究应侧重于根据细胞因子谱抑制炎症、平衡肝细胞死亡和再生、限制固有免疫反应的激活以及维持肠道黏膜完整性。